EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy

Fangyu Liu, Mairepaiti Halimulati, Jing Luo iD, Liqun Jia, Qingwen Tao

WIREs Mechanisms of Disease · 2026-03 · 18 (2-3)

DOI: 10.1002/wsbm.70009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, online erschienen am 17.06.2026. Verfasst von Fangyu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Integrative Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Ferroptosis, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: Capital Health Research and Development of Special Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis, an iron‐dependent form of regulated cell death driven by lipid peroxidation, plays a context‐dependent dual role in tumor immunity and immunotherapy. On one hand, it can act as an immunogenic cell death mechanism, releasing damage‐associated molecular patterns that activate dendritic cells and promote T cell priming. On the other hand, ferroptosis may suppress antitumor immunity by triggering death or dysfunction in key immune cells, including T lymphocytes, dendritic cells, and macrophages. This review synthesizes current insights into the molecular determinants of ferroptosis sensitivity within the tumor microenvironment. It examines how immune cells can induce ferroptosis in cancer cells, and how tumors evolve resistance through upregulation of proteins like GPX4 and FSP1 or metabolic rewiring. The interplay between ferroptosis and immunity offers promising therapeutic avenues, such as combining ferroptosis inducers with immune checkpoint inhibitors or employing nanotechnology for targeted delivery. However, the net immunogenic outcome depends on temporal, cellular, and microenvironmental factors. Future strategies must aim to selectively induce immunogenic ferroptosis in tumors while preserving immune cell function, leveraging biomarkers and microenvironment modulation to optimize combination therapies in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisImmunotherapyNeoplasmsHumansTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

Ferroptosisimmunotherapytherapy strategytumor immunitytumor microenvironment

Autor:innen und Institutionen

  • National Center for Integrative Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • Beijing University of Chinese Medicine, School of Clinical Medicine, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • Nutritional Science Department, The University of Texas at Austin, Austin, USA.

ORCID-Profile: Jing Luo

Förderung

  • Capital Health Research and Development of Special Fund

Zitieren

APA

Liu, F., Halimulati, M., Luo, J., Jia, L., & Tao, Q. (2026). Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy. WIREs Mechanisms of Disease, 18(2-3). https://doi.org/10.1002/wsbm.70009

Vancouver

Liu F, Halimulati M, Luo J, Jia L, Tao Q. Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy. WIREs Mechanisms of Disease. 2026;18(2-3). doi:10.1002/wsbm.70009

BibTeX
@article{Liu2026,
  author = {Liu, Fangyu and Halimulati, Mairepaiti and Luo, Jing and Jia, Liqun and Tao, Qingwen},
  title = {Friend or Foe? The Dual Role of Ferroptosis in Tumor Immunity and Immunotherapy},
  journal = {WIREs Mechanisms of Disease},
  year = {2026},
  volume = {18},
  number = {2-3},
  doi = {10.1002/wsbm.70009}
}
Kostenlos starten →